For the year ending 2025-12-31, VASO had $8,779K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income | 1,569 |
| Depreciation and amortization | 858 |
| Deferred income taxes | -3,050 |
| Loss from investment in eecp global | -408 |
| Gain on sale of subsidiary | 827 |
| Impairment of goodwill | 4,639 |
| Provision for credit losses and commission adjustments | 813 |
| Share-based compensation | 33 |
| Accounts and other receivables | -925 |
| Due from related parties | 494 |
| Inventories | -86 |
| Deferred commission expense | -171 |
| Prepaid expenses and other current assets | 380 |
| Other assets, net | 777 |
| Accounts payable | 600 |
| Accrued commissions | -541 |
| Accrued expenses and other liabilities | 1,456 |
| Sales tax payable | -4 |
| Income taxes payable | -60 |
| Deferred revenue | 3,700 |
| Other long-term liabilities | 490 |
| Net cash provided by operating activities | 9,273 |
| Purchases of equipment and software | 925 |
| Proceeds from sale of vasohealthcare it corp | 200 |
| Net cash (used in) provided by investing activities | -725 |
| Payroll taxes paid by withholding shares | 1 |
| Proceeds from note payable | 3,622 |
| Repayment of notes payable and finance lease obligations | 3,373 |
| Net cash provided by (used in) financing activities | 248 |
| Effect of exchange rate differences on cash and cash equivalents | -17 |
| Net increase in cash and cash equivalents | 8,779 |
| Cash and cash equivalents - beginning of year | 26,271 |
| Cash and cash equivalents - end of year | 35,050 |
VASO Corp (VASO)
VASO Corp (VASO)